The Biotech Reckoning: Why 2026 is Defining a New Era for Medical InnovatorsGlobal Report·Aug 25 at 06:33 AMAMGN-0.33%REGN+0.37%
Cross-Border Realignments: How 7 US Biopharma Players Are Navigating Global Regulatory TensionsGlobal Report·Aug 25 at 04:21 AMBEAM+0.31%IONS-1.62%
Cross-Border Bets and Delisting Clocks: Micro-Cap Biotech Fractures Under Liquidity SqueezeGlobal Report·Aug 19 at 05:12 AMBIYA-0.45%ADTX+13.24%
The Great Healthcare Crossover: SK’s AI Compute Play and Micro-Cap SpinoffsGlobal Report·Aug 16 at 05:13 AMSKHY+0.62%ADTX+13.24%
The Overlooked Summer Shakeups: Spinoffs, FDA Drama, and Insider BetsGlobal Report·Aug 4 at 04:17 AMTRIP-1.82%SRPT+0.58%
The 2026 Biotech Reckoning: Enough With the AI Hype, Show Me the EfficacyGlobal Report·Aug 2 at 04:12 AMGENB-1.96%IBRX-1.55%
Macro Signals Across the Microstructure: What a Diverse Basket Says About Capital FlowsGlobal Report·Jul 30 at 04:13 AMWMB+1.38%EWBC-2.05%
US Biotech Sector Nears Commercialization Inflection Point on Key FDA ApprovalsGlobal Report·Jul 29 at 04:19 AMCRSP-1.18%GENB-1.96%
Capital Shifts Across US Small-Caps: Navigating Bitcoin Treasuries and Biotech MilestonesGlobal Report·Jul 28 at 04:12 AMRSKD-0.16%ADVB-3.14%
Niche Market Moves: Major Overhauls From Energy to AI InfrastructureGlobal Report·Jul 22 at 04:17 AMWLLBW0.00%BMEA+1.73%
The Unbundling of the Long Tail: Strategic Realities in a Post-ZIRP MarketGlobal Report·Jul 18 at 04:13 AMLDOS+0.41%DPRO+18.92%
Aditxt Amends Note Purchase Pact to Add Investor, Swap Notes With No Change in PrincipalTradingView·Jul 17 at 11:13 AMADTX+13.24%
